Prevalence and Risk Factors of Clostridium difficile Infection Among Patients Hospitalized for a Flare of Inflammatory Bowel Disease in King Abdulaziz University Hospital.|https://dx.doi.org/10.7759/cureus.48451
Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.|https://dx.doi.org/10.1007/s10096-023-04729-z
Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice.|https://dx.doi.org/10.1128/aac.00903-23
A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.|https://dx.doi.org/10.7759/cureus.48735
Vowst's FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1097/MS9.0000000000001410
Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023.|https://dx.doi.org/10.1016/j.cmi.2023.12.007
Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.|https://dx.doi.org/10.1007/s10151-023-02878-z
Host Immune Responses to Clostridioides difficile Infection and Potential Novel Therapeutic Approaches.|https://dx.doi.org/10.3390/tropicalmed8120506
Circadian Rhythms and Depression in Adolescents: A Comparative Analysis of First Episode and Recurrent-Episode Groups.|https://dx.doi.org/10.3390/jpm13121665
Development of a Protocol for Anaerobic Preparation and Banking of Fecal Microbiota Transplantation Material: Evaluation of Bacterial Richness in the Cultivated Fraction.|https://dx.doi.org/10.3390/microorganisms11122901
Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.14309/ajg.0000000000002582
Prescription Microbiome Therapeutic for Recurrent Clostridioides difficile Infection: Fecal Microbiota Live-jslm.|https://dx.doi.org/10.14309/ajg.0000000000002577
Peritoneal Dialysis-Associated Peritonitis Caused by Achromobacter xylosoxidans: A Case Report and Literature Review.|https://dx.doi.org/10.1177/23247096231220467
Bacterial microbiome changes after fecal transplantation for recurrent Clostridioides difficile infection in the Brazilian center.|https://dx.doi.org/10.1007/s42770-023-01227-4
Clostridioides difficile Biofilm.|https://dx.doi.org/10.1007/978-3-031-42108-2_12
Comparative Genomics of Clostridioides difficile.|https://dx.doi.org/10.1007/978-3-031-42108-2_10
Immunization Strategies Against Clostridioides difficile.|https://dx.doi.org/10.1007/978-3-031-42108-2_7
Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0.|https://dx.doi.org/10.1007/978-3-031-42108-2_5
European Practice for CDI Treatment.|https://dx.doi.org/10.1007/978-3-031-42108-2_4
Economic Burden of Clostridioides difficile Infection in European Countries.|https://dx.doi.org/10.1007/978-3-031-42108-2_1
Erratum: Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.14309/ajg.0000000000002649
